Loading
Latest filing published 15 Sept 2026 for FibroBiologics, Inc., €433k.
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
All filings by Hamid Khoja on record concern FibroBiologics, Inc. In total, 4 filings cover trades dated from 12 August 2024 to 15 September 2026.
Every open-market trade on record is a purchase: 3 purchases worth €42k, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 1 share grant. So far in 2026, the count stands at 1 purchase and no sales.
Half of the purchases are above €15k and half below. Clusters matter here: 2 out of 3 purchases overlapped with buying by a colleague within 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.
The latest filing, published on 15 September 2026, reports a share grant of €433k in FibroBiologics, Inc. The most recent open-market purchase was published on 5 March 2026, 233 days ago. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations